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J. Girbés15,18, S. Gaztambide1,4,5,18, E. Delgado5,10,18, F. J. Chaves1,16,18, L. Castaño1,4,5,18, 
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Our aim was to evaluate whether fatty liver index (FLI) is associated with the risk of type 2 diabetes 
(T2DM) development within the Spanish adult population and according to their prediabetes 
status; additionally, to examine its incremental predictive value regarding traditional risk factors. 
A total of 2260 subjects (Prediabetes: 641 subjects, normoglycemia: 1619 subjects) from the Di@
bet.es cohort study were studied. Socio‑demographic, anthropometric, clinical data and survey on 
habits were recorded. An oral glucose tolerance test was performed and fasting determinations of 
glucose, lipids and insulin were made. FLI was calculated and classified into three categories: Low 
(< 30), intermediate (30–60) and high (> 60). In total, 143 people developed diabetes at follow‑up. 
The presence of a high FLI category was in all cases a significant independent risk factor for the 
development of diabetes. The inclusion of FLI categories in prediction models based on different 
conventional T2DM risk factors significantly increase the prediction power of the models when all 
the population was considered. According to our results, FLI might be considered an early indicator 
of T2DM development even under normoglycemic condition. The data also suggest that FLI could 
provide additional information for the prediction of T2DM in models based on conventional risk 
factors.
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Non-alcoholic fatty liver disease (NAFLD) is characterized by increased fat storage in form of triglycerides in 
the liver (exceeding 5% of its weight) in absence of excessive alcohol  consumption1. It is the most frequent liver 
disease in Western countries with an estimated overall worldwide prevalence in the adult population of about 
25%2, value that is substantially increased in subjects with type 2 diabetes (T2DM)2. A recent study in the United 
States population has reported the presence of NAFLD in up to 78–85% of patients with T2DM, based on the 
use of different non-invasive markers of liver  steatosis3. Specifically in Spain, the prevalence of NAFLD has been 
estimated to be 26% among the adult  population4.
NAFLD is associated with several liver disorders, terminal liver failure and hepatocellular  carcinoma5, car-
diovascular  disease6 and it is considered as the hepatic manifestation of metabolic  syndrome7,8. Additionally, 
increasing epidemiological evidence suggests a bidirectional relationship between NAFLD and T2DM may be 
linked by insulin  resistance9–11. This concept would be in line with several studies that have consistently shown 
that NAFLD is an independent risk factor for prediabetes or  T2DM12–14. Given the progressive nature of the 
disease and its risk of adverse consequences, health care providers are strongly advised to screen for NAFLD in 
all patients with diabetes and to be more proactive in their  management11.
The gold standard for diagnosis of NAFLD is the liver biopsy, which is an invasive technique only justified 
in severe liver  disease15. 1H-magnetic resonance spectroscopy (MRS) allows a quantification of hepatocellular 
lipid content and an exact diagnosis of  steatosis15, while ultrasound and computed tomography provide semi-
quantitative  estimations16. These techniques are time-consuming, expensive and often unavailable in the daily 
routine. As an alternative, several panels or ‘scores’ consisting of combinations of anthropometric and biochemi-
cal parameters have been developed for the diagnosis and quantification of steatosis. Among all of them, the fatty 
liver index (FLI) has gained  popularity17,18. FLI is a non-invasive and well-established method for the diagnosis 
of fatty liver validated against  ultrasound17–20 and  MRS21 in both Asian and Western populations. It includes 4 
variables: body mass index (BMI), waist circumference, serum triglycerides and serum gamma-glutamyl trans-
ferase (GGT)18.
Several previous studies, have reported that FLI is a predictor for the development of T2DM in the general 
 population22–24 and in subjects who have an especially higher risk of DM2 (prediabetic status)14,25–27. Accord-
ingly, FLI could be potentially useful to further identify those who are at higher risk of conversion to new onset 
of T2DM in order to initiate primary prevention efforts with aggressive lifestyle  management28. Nevertheless, 
the additive predictive value of FLI beyond the conventional risk factors of T2DM has been investigated less 
and with inconclusive  results23,25. In the same way, it is unclear whether FLI is associated with the development 
of T2DM in individuals without prediabetes who might be at lower risk for incident T2DM. To our knowledge, 
only one study performed in a Japanese population has reported the potential utility of FLI as a predictor for 
T2DM development in subjects without  hyperglycemia29.
Therefore, the aim of this study was to evaluate whether fatty liver estimated by FLI is associated with the risk 
of T2DM within the Spanish adult population with and without prediabetes. In addition, we also examined the 
incremental predictive value of FLI in diagnosing individuals who will develop new-onset T2DM over 7.5 years 
of follow-up in the Spanish general adult population and according to the prediabetes status.
Results
Baseline characteristics of the population. The baseline characteristics of the subjects according to 
FLI categories in the overall population and the groups of subjects with and without prediabetes are presented in 
Table 1. For all the cases, groups of subjects in the low FLI category were younger and with a lower percentage of 
men than the rest of FLI categories. In general, anthropometric variables, clinical parameters and lifestyle factors 
were different according to FLI categories for all the studied population groups.
Compared to the low FLI category, individuals in the high FLI category had higher fasting glucose levels (FGL) 
except in the group with prediabetes, where no differences in FPG according to FLI categories were found. No 
differences in the family history of T2DM or in the adherence to the Mediterranean diet were found according 
to FLI categories for any group.
New onset of T2DM. 143 people developed T2DM after 7.5 years of follow-up, among them 106 had pre-
diabetes at baseline. The proportions of subjects who develop T2DM were significantly different according to the 
FLI categories in all the studied groups (Overall population: 1.77% within low FLI category, 4.90% within inter-
mediate FLI category and 13.04% within high FLI category. Subjects with normoglycemia: 0.73% within low FLI 
category, 2.7% within intermediate FLI category and 5.13% within high FLI category. Subjects with prediabetes: 
8.08% within low FLI category, 10.36% within intermediate FLI category and 22.07% within high FLI category. 
p < 0.001 for all cases measured by a Chi-Square test.). Proportion of subjects who develop T2DM within each 
FLI category according to sex is showed in Supplementary Table S1.
FLI as a T2DM development biomarker. We analyzed incidence rate ratios (RR) of FLI and each com-
ponent (BMI, waist circumference, serum triglycerides and GGT) for new-onset of T2DM in overall population. 
As a result, we found that FLI and its components were significantly associated to incident T2DM (RR[95% CI]: 
FLI = 1.03[1.02–1.3]; BMI = 1.12[1.09–1.15]; waist circumference = 1.05[1.04–1.06]; triglycerides = 6.90[3.60–
13.20] and GGT = 4.08[2.86–5.84]. p < 0.001 in all the cases).
Multivariate analyses for the development of T2DM at 7.5 years of follow-up in overall population (Table 2) 
and in subjects classified according to their prediabetes status at baseline (Table 3) were also performed. Results 
from these multivariate models adjusted by different confounding variables showed that the presence of a high 
FLI category was in all cases a significant independent risk factor for the development of T2DM with a significant 
p for trend for the increased incidence RR associated with higher FLI categories in overall population (Table 2), 
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and also in subjects under normoglycemia or prediabetes conditions (Table 3). Significant independent associa-
tions remained when FLI was considered as continuous variable (Supplementary Table S2).
Separate analyses by sex returned similar results in overall population (Supplementary Table S3). When 
population is split by prediabetes status, the RR values for the association between FLI and T2DM incidence were 
similar between men and women in all regression models, both in subjects with normoglicemia and prediabetes 
(Supplementary Table S4); nevertheless, associations remained significant mainly in the group of women with 
normoglicemia where the sample size was also higher.
Table 1.  Baseline characteristics of the subjects according to FLI categories. p = signification level of sex, age 


























Age (years) 42.61 ± 13.77 50.56 ± 14.45 52.87 ± 13.92 < 0.001 41.65 ± 13.52 49.19 ± 14.14 51.20 ± 14.26 < 0.001 48.30 ± 13.91 53.98 ± 14.70 54.71 ± 13.35 < 0.001
Sex (% 
men) 21.8 48.3 56 < 0.001 21.5 49.1 56.2 < 0.001 23.5 46.3 44.3 < 0.001
BMI (kg/
m2) 23.92 ± 2.63 27.79 ± 2.43 32.14 ± 4.20 < 0.001 23.78 ± 2.61 27.66 ± 2.40 31.86 ± 4.08 < 0.001 24.78 ± 2.63 28.12 ± 2.47 32.44 ± 4.31 < 0.001
Waist (cm) 81.03 ± 8.20 94.11 ± 6.13 105.06 ± 9.38 < 0.001 80.53 ± 8.22 94.11 ± 6.15 104.14 ± 9.31 < 0.001 84.05 ± 7.40 94.12 ± 6.11 106.11 ± 9.35 < 0.001
Cholesterol 
(mg/dl) 186.68 ± 37.64 204.35 ± 37.80 207.86 ± 37.07 < 0.001 184.98 ± 37.07 204.43 ± 37.85 207.54 ± 35.91 < 0.001 196.81 ± 39.49 204.15 ± 37.80 208.45 ± 38.60 < 0.001
cHDL (mg/
dl) 57.44 ± 13.52 52.57 ± 11.55 47.77 ± 10.95 < 0.001 57.07 ± 13.55 51.97 ± 11.29 47.32 ± 10.92 < 0.001 59.63 ± 13.14 54.04 ± 12.07 48.20 ± 11.07 < 0.001
cLDL (mg/




79.34 ± 28.18 110.50 ± 42.72 159.36 ± 97.81 < 0.001 78.81 ± 27.90 110.93 ± 43.11 105.84 ± 60.05 < 0.001 82.86 ± 29.75 109.44 ± 41.87 131.38 ± 91.03 < 0.001
Glucose 
(mg/dl) 86.98 ± 11.47 93.50 ± 10.11 97.31 ± 10.86 < 0.001 84.55 ± 9.98 89.19 ± 7.45 90.45 ± 7.22 < 0.001 101.65 ± 8.57 104.20 ± 7.61 105.13 ± 8.84 0.38
Insulin 
(mUI/ml) 6.28 ± 4.09 8.24 ± 3.72 11.65 ± 6.05 < 0.001 6.10 ± 3.82 7.83 ± 3.39 10.39 ± 4.66 < 0.001 7.36 ± 5.37 9.26 ± 4.29 13.12 ± 7.07 < 0.001
HOMA-IR 1.37 ± 1.01 1.92 ± 0.94 2.84 ± 1.66 < 0.001 1.29 ± 0.88 1.73 ± 0.78 2.33 ± 1.09 < 0.001 1.86 ± 1.49 2.39 ± 1.13 3.43 ± 1.98 < 0.001
AST (U/l) 15.88 ± 5.13 17.79 ± 5.26 20.09 ± 8.97 < 0.001 15.80 ± 5.26 17.75 ± 5.34 19.79 ± 8.52 < 0.001 16.52 ± 4.58 17.87 ± 5.06 20.42 ± 9.46 0.002
ALT (U/l) 11.36 ± 5.81 13.93 ± 7.15 18.50 ± 13.48 < 0.001 11.26 ± 5.93 14.13 ± 7.62 18.01 ± 11.73 < 0.001 11.98 ± 4.92 13.43 ± 5.81 19.06 ± 15.26 < 0.001
Hyperten-









33.2 37.8 36.9 0.12 32.2 38.9 35.3 0.07 39.1 35.2 38.7 0.71
Steatogenic 
drugs (%) 7.6 9.5 11.1 0.05 6.9 9.1 9.0 0.26 11.7 10.3 13.5 0.59
Smoking 
(%) 26.4 27.5 23.4 < 0.001 28.1 29.7 24.1 < 0.001 16.2 22.0 22.6 < 0.001
Educational level (%)









72.4 73.6 76.3 72 73.2 79.5 75.0 74.4 72.7
University 24.2 16.3 11.1 24.8 17.4 11.5 20.6 13.4 10.6
Alcohol consumption






Low 12.7 8.9 8.2 13.3 9.1 8.2 9.6 8.6 8.2
Moderate 49.3 53.3 49.7 49.1 53.3 51.0 50.7 53.4 48.1
High 13.4 16.1 19.3 11.9 16.7 18.5 22.1 14.7 20.2
IPAQ





0.001Moderate 41.1 31.1 27.9 37.4 31.0 31.4 37.5 31.3 33.1
High 49.8 32.2 17.9 24.8 28.5 20.6 27.9 26.4 15.0
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Predictive value of FLI. To compare the predictive value of FLI for the risk of new cases of T2DM regard-
ing the individual variables include in its calculation, we performed comparisons of receiver operating (ROC) 
curves of these prediction models. Analysis of these ROC curves showed that the AUC was significantly increased 
in the model with FLI versus the models with its components (Supplementary Figure S1).
Additionally, we performed ROC curves for new cases of T2DM of two proposed models which include or 
not the FLI categories. The first proposed model (PM1) was based on the conventional risk factors for T2DM 
development age, sex, FGL, background of T2DM, and insulin resistance risk category (HOMA-IR). The second 
proposed model (PM2) was based on PM1 but excluding HOMA-IR considering the difficulties to determine 
HOMA values routinely in clinical practice.
The addition of FLI categories to both PM1 and PM2 models in the overall population is shown in Fig. 1. 
The AUC for predicting future incidence of T2DM significantly increased when FLI was added to both diabetes 
prediction models (Fig. 1). We also assessed whether the addition of FLI to the conventional T2DM prediction 
models can improve the predictive ability for new-onset T2DM using NRI and  IDI30. We found that the IDI 
values were − 0.010 (95% CI: − 0.016 to − 0.004, p = 0.01) for the PM1 model, and − 0.016 (95% CI: − 0.027 to 
− 0.026, p = 0.02) for the PM2 model. Additionally, the category-free NRI were 0.066 (standard error = 0.021, 
z-score = 2.004, p = 0.045) and 0.07 (standard error = 0.027, z-score = 2.57, p = 0.001) for the PM1 and PM2 models 
respectively. Thus, the addition of FLI to these basic diabetes risk models correctly reclassified 6.6% and 7% more 
cases respectively in the overall study population.
Alternatively, when the prediabetes status was considered, the inclusion of the FLI categories in the PM1 
model slightly increased the AUC with no significant differences independently of the prediabetes status (Fig. 2). 
However, the inclusion of FLI categories in the model excluding insulin resistance status (PM2) resulted in a 
significant increment of the AUC in comparison with the model without FLI, both in normoglycemic (Fig. 2A) 
and subjects with prediabetes (Fig. 2B). NRI and IDI values for the potential predictive improvement associated 
with these incremented AUCs were not significant.
Table 3.  Incidence rate ratios and 95% confidence intervals of Poisson robust multivariate regression models 
for the risk of incident T2DM after 7.5 years of follow-up according to FLI categories and prediabetes status. 
pa = Significance level in the regression model. pb = Significance level in the p for trend test. RC reference 
category.
Low FLI Intermediate FLI High FLI pa pb
Subjects with normoglycemia (1619)
Base model: age, sex, fasting glucose and family history of T2DM RC 2.40 (0.80–7.21) 4.10 (1.48–11.33) < 0.01 < 0.01
Base model + HOMA-IR RC 2.34 (0.79–6.95) 3.75 (1.30–10.81) 0.01 0.01
Base model + total and HDL and LDL cholesterol + dyslipidemia treatment RC 2.43 (0.79–7.44) 3.90 (1.48–10.26) < 0.01 < 0.01
Base model + AST + ALT + steatogenic medications RC 2.35 (0.78–7.12) 3.69 (1.31–10.39) 0.01 < 0.01
Base model + hypertension RC 2.24 (0.71–7.03) 4.13 (1.45–11.76) < 0.01 < 0.01
Base model + alcohol consumption + educational level + smoking habits + Mediterranean diet adher-
ence + physical activity RC 2.21 (0.73–6.73) 4.31 (1.54–12.09) < 0.01 < 0.01
Subjects with prediabetes (641)
Base model: age, sex, fasting glucose and family history of T2DM RC 1.05 (0.51–2.17) 2.28 (1.24–4.18) < 0.01 < 0.01
Base model + HOMA-IR RC 1.03 (0.49–2.15) 2.17 (1.14–4.15) 0.02 < 0.01
Base model + total and HDL and LDL cholesterol + dyslipidemia treatment RC 0.95 (0.46–1.93) 1.88 (1.01–3.50) 0.05 0.01
Base model + AST + ALT + steatogenic medications RC 1.04 (0.50–2.13) 2.28 (1.24–4.20) < 0.01 < 0.01
Base model + hypertension RC 1.06 (0.51–2.20) 2.31 (1.22–4.39) 0.01 < 0.01
Base model + alcohol consumption + educational level + smoking habits + Mediterranean diet adher-
ence + physical activity RC 1.05 (0.52–2.15) 2.23 (1.21–4.08) 0.01 < 0.01
Table 2.  Incidence rate ratios and 95% confidence intervals of Poisson robust multivariate regression models 
for the risk of incident T2DM after 7.5 years of follow-up according to FLI categories in the general population. 
pa = Significance level in the regression model. pb = Significance level in the p for trend test. RC reference 
category.
Low FLI Intermediate FLI High FLI pa pb
Base model: age, sex, fasting glucose and family history of T2DM RC 1.54 (0.83–2.85) 3.16 (1.81–5.52) < 0.001 < 0.001
Base model + HOMA-IR RC 1.49 (0.80–2.78) 2.93 (1.63–5.27) < 0.001 < 0.001
Base model + total and HDL and LDL cholesterol + dyslipidemia treatment RC 1.41 (0.76–2.62) 2.69 (1.53–4.71) 0.001 < 0.001
Base model + AST + ALT + esteatogenic medication RC 1.50 (0.80–2.78) 2.99 (1.70–5.26) < 0.001 < 0.001
Base model + hypertension RC 1.48 (0.79–2.78) 3.15 (1.76–5.63) < 0.001 < 0.001
Base model + alcohol consumption + educational level + smoking habits + Mediterranean diet adher-
ence + physical activity RC 1.47 (0.80–2.73) 3.13 (1.79–5.47) < 0.001 < 0.001
5
Vol.:(0123456789)
Scientific Reports |        (2021) 11:16453  | https://doi.org/10.1038/s41598-021-95546-x
www.nature.com/scientificreports/
No significant differences were found in any of the studied groups comparing PM1vs PM2 AUCs in models 
with FLI; nor in models without FLI.
Discussion
In this cohort of the Spanish adult population, we found that FLI levels were positively associated with the risk of 
incident T2DM after 7.5 years follow-up, independently of different risk factors for diabetes such as age, sex, FGL, 
family history of T2DM, HOMA-IR, plasma lipids, hypertension or lifestyle. We also showed that the association 
of FLI with the development of T2DM remained within the normoglycemic Spanish population, even though 
the risk of diabetes in this group was lower. Moreover, we found that models including categorized FLI correctly 
reclassified a substantial proportion of incident T2DM cases of the Spanish overall population independently of 
the presence of the HOMA-IR in the prediction models.
Increasing epidemiological evidence suggests that there is a bidirectional relationship between NAFLD and 
T2DM which may be linked by insulin  resistance12–14. In relation to this, FLI is not only considered a good 
marker for fatty liver in clinical practice, but it has also been suggested as a rough clinical estimate of abnormal 
insulin sensitivity and  secretion21.
The majority of previous studies have shown that higher FLI levels might be a predictor of the development of 
incident T2DM in the general  population23,24,27 and in patients with  prediabetes14,25,26 independently of different 
confounding variables. According to these, in our study, in all models the highest FLI category was significantly 
associated with the development of incident T2DM after 7.5 years in the general population and within subjects 
with prediabetes. Franch-Nadal et al. have previously published the association of FLI-diagnosed hepatic steatosis 
with the risk of developing T2DM in the Spanish population with prediabetes at a shorter follow-up period; 
nevertheless, unlike our investigation, the lack of data on HOMA values did not allow them to disentangle the 
respective effects of HOMA-IR and FLI on the risk of T2DM development. Contrary to our findings, data from 
the IT-DIAB  study25, in which the association between FLI and T2DM conversion was studied in a sample of 
389 subjects with prediabetes from three different French cities, indicated that after including the HOMA levels 
in their multivariate analysis, the FLI was no longer significantly associated with conversion to new onset of 
T2DM. This difference could be potentially explained, as some of the authors declared in the study limitations, 
by their limited sample size and the lack of statistical power to draw adequate mixed models.
Our results also show for the first time that high FLI levels are associated with the risk of T2DM development 
in normoglycemic subjects from a European population. Moreover, this association was also independent of 
other confounding variables such as sex, age, baseline FGL, family history of T2DM, lifestyle, hypertension, lipid 
profile, level of transaminases and insulin resistance risk category. To the best of our knowledge, only one other 
Figure 1.  Comparison of area under the receiver-operating characteristic curve (AUC) for incident T2DM in 
overall population according to adding or not FLI to the conventional T2DM prediction risk models PM1 (age, 
sex, family history of T2DM, fasting glucose level and insulin resistance risk category) and PM2 (age, sex, family 
history of T2DM and fasting glucose level).
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study has been performed so far assessing the association of FLI levels and incidence of T2DM in normoglycemic 
 subjects29. This study was performed in a Japanese population and concurs with our current results, higher FLI 
levels were found to be a predictor of incident T2DM in individuals without prediabetes according to a model 
Figure 2.  Comparison of area under the receiver-operating characteristic curve (AUC) for incident T2DM in 
subjects with and without prediabetes according to adding or not FLI to the conventional T2DM prediction risk 
models PM1 (age, sex, family history of T2DM, fasting glucose level and insulin resistance risk category) and 
PM2 (age, sex, family history of T2DM and fasting glucose level).
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adjusted by age, systolic blood pressure, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, 
smoking and alcohol consumption status. However, unlike our investigation, the impact of insulin resistance on 
the relationship between FLI and T2DM was not examined in their study.
In our study, FLI was able to significantly increased AUC for the future T2DM compared to the variables 
included in its calculation; additionally, the incorporation of FLI into traditional T2DM risk prediction models 
including age, sex, FGL, family background of T2DM, with and without HOMA-IR, significantly improved the 
prediction AUC of T2DM development after 7.5 years of follow-up in the Spanish general population. Similar 
results have been reported by Yadav et al.23 in a Japanese population where they also observed that, opposite 
to the FLI, the addition of BMI and/or waist circumference to the conventional T2DM prediction model did 
not significantly improve the AUC values. To further explore the added value of FLI as a T2DM predictor, we 
calculated the specific statistical metrics IDI and NRI, which are known to be more sensitive than AUC for the 
determination of improvement in the predictive  value30. IDI can provide clinical information on increased sen-
sitivity without sacrificing specificity and NRI can provide clinical information by quantifying the improvement. 
According to our knowledge, only the KoGES-ARIRANG Japanese study has reported information about the 
incremental predictive value of FLI on the risk of T2DM development with IDI and NRI  data23. Similar to this 
previous work, our current study showed for the overall Spanish population that FLI improved incident T2DM 
subject reclassification with both significant IDI and NRI, independently of the presence of the HOMA-IR in 
the prediction models. Additionally, when comparing the ROC curves of models including or not the insulin 
resistance risk category, non-significant differences for better predicting T2DM development were found. Alto-
gether, these data suggest that for the general Spanish population, FLI not only act as an additional contributor 
to predicting incident T2DM when applied with these conventional risk factors, but it could also be considered 
as an effective and efficient alternative to HOMA determination in clinical practice to evaluate the risk of T2DM 
development avoiding the cost of the circulating insulin determination.
When comparing AUCs from the ROC curves in the groups of subjects according to the prediabetes status, 
the improvement resulting from the inclusion of FLI in the prediction models was only significant when these 
models excluded HOMA-IR category. Nevertheless, non-significant reclassification improvement estimated by 
NRI nor IDI statistics was found after the inclusion of FLI in any of the models. No previous data have been 
published so far regarding the quantification of the predictive value of FLI in the development of T2DM by either 
using NRI or IDI methods according to the prediabetes status.
Our study presents some limitations. Even if FLI was first proposed as a good readout of hepatic  steatosis18, we 
were not able to confirm hepatic steatosis in our population as relevant imaging data. Subjects with severe diseases 
such as hepatitis were excluded from the cohort; however, participants were not screened for other different forms 
of liver disease. Although participation in the follow-up was 66%, the possible participation bias was  minimal31; 
nevertheless, the limited sample size when the overall population is split according to prediabetes status might be 
the cause of the lack of significant differences between AUCs and NRI and IDI values. Alternatively, sample size 
might be also limited to detect significant associations in the analysis men and women separately when overall 
population is split by the prediabetes status (especially in the group of subjects with prediabetes); nevertheless, 
RR for the association between categories of FLI and T2DM incidence were similar between men and women, 
which let us to believe that there were not differences between men and women and the lack of significant associa-
tions was mainly due to a limited sample size; to avoid possible interferences related to the sex, we included it as 
confounding variable in all the multivariate models. Prescription drugs are a well-known cause of hepatotoxicity 
and although the use of some of the most known steatogenic drugs has been considered in the models adjust-
ment, the list of these medications is long and heterogeneous and it was impossible to assess the effects of other 
medications. There could also be an underdiagnosis in the declared interpretation of the subjects in relation 
to their pharmacological treatments and this cannot be ruled out. As it is common in epidemiological studies, 
HOMA index was used to estimate insulin resistance instead of performing the clamp method. HOMA-IR index 
has been validated against the gold-standard hyperinsulinaemic euglycaemic clamp (an invasive, intensive and 
technically difficult procedure), and is considered a reliable index to assess insulin sensitivity in epidemiological 
studies which assess “in vivo” insulin sensitivity in  humans32. Even that in our results FLI showed a significantly 
higher predicting T2DM AUC values than its individual components, and although previous investigations have 
reported that the addition of BMI and/or waist circumference to conventional T2DM prediction model did not 
significantly improve the AUC  values23; it is likely that the improvement observed in the AUC after the incorpo-
ration of FLI into the MP1 and MP2 models, might be related to the variables included in the FLI calculation, 
then this result should be carefully considered.
The main strength of the study is that the data were obtained from a large national wide-cohort, with a 
considerable duration of the follow-up and substantial number of events. Most of the participants underwent 
an OGTT to diagnose T2DM or prediabetes, and in the follow-up, HbA1c was also used, which guarantees the 
capture of most of the incident T2DM.
In conclusion, data gathered from this national cohort demonstrated an independent association between the 
high FLI category and the risk of incident T2DM. Our results also indicate that FLI, a simple surrogate measure 
of hepatic steatosis, may be considered as an early indicator of T2DM not only in both the general population 
and subjects with prediabetes, but also in subjects with normal glucose levels. Our current investigation also 
suggest that FLI might provide additional information for future T2DM to prediction models including the 
conventional risk factors sex, age, FGL and insulin resistance risk category. In addition, this index might be 
useful as an alternative to HOMA in clinical practice to evaluate future T2DM risk. Further investigations are 
needed to confirm the predictive value of FLI in groups of individuals with and without prediabetes, as well as 
to generalize the value of this risk-scoring tool for predicting incident T2DM.
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Methods
Study design, setting and population. Samples and data were based on the population-based, cohort 
study Di@bet.es epidemiological trial.
The initial cross-sectional study of the Di@bet.es was undertaken in 2008–2010 from a random cluster sam-
pling of the Spanish  population33. The Di@bet.es study sample consisted of 5072 subjects more than 18 years old, 
randomly selected from National Health System registries distributed into 100 clusters. Subjects with severe dis-
ease such as cancer or hepatitis were excluded by protocol. The Di@bet.es cohort was re-evaluated in 2016–2017 
(the follow-up time was 7.5 ± 0.6 years) and finally 2408 subjects completed the follow-up. Detailed information 
on the methodology of the Di@bet.es cohort study has been previously  described31.
For the present sub-study only followed up participants at risk of T2DM (who had not T2DM at baseline) and 
from which FLI levels were possible to calculate were included in the analyses (n = 2260). The study population 
was classified according to the presence (n = 641) or absence (n = 1619) of prediabetes at baseline, which was 
defined as having FGL ≥ 100 mg/dl and/or post OGTT glucose level ≥ 140 and < 200 mg/dl.
The research was carried out in accordance with the Declaration of Helsinki (WHO 2011) of the Word Medi-
cal Association. Written informed consent was obtained from all the participants. The study was approved by the 
Ethics and Clinical Investigation Committee of the Hospital Regional Universitario de Málaga (Malaga, Spain) 
in addition to other regional ethics and clinical investigation committees all over Spain.
Data collection and laboratory measurements. In both phases of the study, the participants were 
invited to attend an examination visit at their health centre with a nurse specially trained for this project. Infor-
mation was collected using an interviewer administered structured questionnaire, followed by a physical exami-
nation and blood sampling.
For the present study the anthropometric and sociodemographic variables considered were: age, sex, weight, 
waist, family history of T2DM; educational level (classified as unlettered, attendance to primary or high school, 
and university); alcohol consumption (never: no alcohol consumption, low: < 1 serving/week, moderate: between 
1 serving/week and 2 servings/day for men and 1 serving/day for women, and high: > 2 servings/day for men and 
over 1 serving/day for women); adherence to the Mediterranean diet (a 14-point Mediterranean diet score was 
 calculated31 and the cut-off for considering adherence was over 8 points in the score); physical activity (classi-
fied as low, moderate and high levels according to the IPAQ  questionnaire34); smoking habits (current smokers 
vs former/never been smokers). The use of steatogenic  medications35 (amiodarone, methotrexate, tamoxifen, 
fluoxetine, valproic acid, acetylsalicylic acid or nonsteroidal anti-inflammatory drugs) has been also considered.
Also, clinical variables such as blood pressure levels, fasting levels of glucose, insulin and lipid profile (total 
cholesterol, high-density lipoprotein, low-density lipoprotein and triglycerides (TAG)) and transaminases (GGT, 
aspartate transaminase (AST) and alanine transaminase (ALT) were considered.
BMI was calculated. Insulin resistance was estimated by the homeostasis model assessment (HOMA)36, 
and the HOMA 75th percentile of our population excluding subjects with T2DM was calculated as the insulin 
resistance risk category (HOMA-IR).
FLI calculation. The FLI levels were calculated as a surrogate marker of hepatic steatosis based on the meas-
ures of TAG, GGT, BMI and waist circumference, using the formula  described18. FLI values (ranging from 0 to 
100) were also classified into three categories: low FLI (levels < 30), intermediate FLI (levels between 30 and 60) 
and high FLI (levels > 60), as it was established to rule out (low FLI category) and confirm (high FLI category) 
the presence of  NAFLD18.
Definition of new cases of T2DM. New cases of T2DM at follow up were diagnosed as fasting serum 
glucose equal or higher than 126 mg/dl or 2 h post OGTT equal or higher than 200 mg/dl or HbA1c equal or 
higher than 6.5% or use of glucose-lowering medication at the follow-up  examination37.
Statistical analysis. Data are presented as means ± SD, or proportions. Differences in baseline variables 
according to FLI categories were measured by ANOVA adjusted by sex, age and BMI or Chi-square test. Vari-
ables not following a normal distribution were log-transformed to perform the ANOVA analyses.
Incidence rate ratios of T2DM according FLI categories were calculated in the overall population and in the 
group of subjects with and without prediabetes using Poisson Robust Regression  models38 adjusted by different 
potential confounders (age, sex, FGL, family history of T2DM, HOMA-IR, physical activity, adherence to the 
Mediterranean diet, AST and ALT, steatogenic medications, alcohol consumption, educational level, hyperten-
sion and/or serum lipids levels).
The discrimination power of the proposed models with and without FLI was tested by ROC curves analy-
sis. Differences in the ROC curves were tested by the Delong’s test. Furthermore, we used net reclassification 
improvement (NRI) and integrated discrimination index (IDI)30 to quantify the improvement in reclassifica-
tion and sensitivity based on the addition of FLI to proposed models including the conventional risk factors for 
prediction of incident T2DM age, sex, family history of T2DM, FGL, with and without HOMA-IR.
Analyses were made using SPSS v20 (IBM, Chicago, IL, USA).
Appendix
Di@bet.es-incidence Study Group:
G. Rojo-Martínez, F. Soriguer, S. Valdés, N. Colomo, C. Maldonado, E. García-Escobar, A. Lago-Sampedro 
and S. García-Serrano (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas 
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Asociadas [CIBERDEM]; UGC Endocrinología y Nutrición, Hospital Regional Universitario, Instituto de Inves-
tigación Biomédica de Málaga [IBIMA], Malaga, Spain), A. Goday (Servicio de Endocrinología y Nutrición, 
Hospital del Mar, Barcelona, Spain), E. Bordiú (Laboratorio de Bioquímica, Hospital Universitario San Carlos, 
Madrid, Spain), A. Calle-Pascual (Servicio de Endocrinología y Nutrición, Hospital Universitario San Carlos, 
Madrid, Spain and CIBERDEM), L. Castaño and I. Urrutia (CIBERDEM; Unidad de Investigación, Hospital 
Universitario Cruces, Universidad del País Vasco/Euskal Herriko Unibertsitatea [UPV/EHU], Baracaldo, Vizcaya, 
Spain), C. Castell (Servicio de Prevención enfermedades crónicas no transmisibles, Departamento de Salud. 
Barcelona, Spain, E. Delgado and E. Menéndez (Servicio de Endocrinología y Nutrición, Hospital Central de 
Asturias, Oviedo, Asturias, Spain), J. Franch-Nadal (Equipo de Atención Primaria Raval Sud, Institut Català de 
la Salut, Red GEDAPS [Grupo de Estudio de la Diabetes en Atención Primaria de la Salud], Unitat de Suport 
a la Recerca, Institut d’Investigació en Atenció Primària Jordi Gol, Barcelona, Spain), S. Gaztambide (CIBER-
DEM; Servicio de Endocrinología y Nutrición, Hospital Universitario de Cruces, UPV/EHU, Baracaldo Vizcaya, 
Spain), J. Girbés (Unidad de Diabetes, Hospital Arnau de Vilanova, Valencia, Spain), R. Gomis (CIBERDEM; 
IDIBAPS, Hospital Clínic de Barcelona, Barcelona, Spain), E. Montanya (Bellvitge Hospital-IDIBELL, University 
of Barcelona, Hospitalet de Llobregat, Barcelona, Spain), E. Ortega (CIBEROBN; IDIBAPS, Hospital Clínic de 
Barcelona, Barcelona, Spain), I. Ramis (CIBERDEM, Spain), J. Vendrell (CIBERDEM; Rovira i Virgili University; 
Servicio de Endocrinología y Nutrición, Hospital Universitario Joan XXIII, Institut d’Investigacions Sanitàries 
Pere Virgili, Tarragona, Spain).
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